Core Viewpoint - The company expects a significant increase in profit for the fiscal year ending December 31, 2025, projecting a profit between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to a profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Financial Projections - The anticipated adjusted profit totals are expected to range from $91 million (approximately HKD 708 million) to $98 million (approximately HKD 763 million) [1] - The expected profit increase is primarily attributed to the continuous growth of the company's recurring revenue [1] Revenue Drivers - Recurring revenue growth is driven by ongoing research collaborations with partners such as AstraZeneca and Bristol-Myers Squibb [1] - The global partnership network is expanding, with revenue from innovative product licensing and collaborations becoming a significant source of recurring income, including licensing agreements with Otsuka Pharmaceutical and Windward Bio [1] - Rapid growth in the business of Nona Bio is noted, including revenue from technology licensing and platform-based services, as well as milestone payments from existing collaborations, such as research and technology licensing agreements with Pfizer [1]
和铂医药-B发盈喜 预期年度溢利约8800万美元至9500万美元